North America Pemetrexed Market Size & Outlook, 2025-2033


North America Pemetrexed Market Insights

  • As highlighted in Reed Intelligence analysis, the North America Pemetrexed Market, valued at USD 880.54 Million in 2024, is estimated to achieve USD 1025.45 Million by 2033.
  • The market is estimated to grow at a CAGR of 1.69% spanning 2026 to 2033.
  • By market size, Malignant Pleural Mesothelioma led the By Application category in 2024.
  • The By Application segment led by Malignant Pleural Mesothelioma is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • In 2024, North America contributed 37.63% to the overall global Pemetrexed Market size.
  • By 2033, United States is anticipated to dominate the global market based on market size.
  • Canada is expected to witness the fastest growth within North America, attaining USD 287.86 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 880.54 Million
Market Size In 2033 USD 1025.45 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.69% (2025-2033)
Segmnetation Covered
North America
  1. United States
  2. Canada
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends